Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Sartorius Stedim Biotech ( (FR:DIM) ).
The announcement from Sartorius Stedim Biotech pertains to the number of shares and voting rights that constitute the company’s issued capital as of January 1, 2025. The total number of shares is reported as 97,330,405, with theoretical voting rights totaling 165,560,444 and net voting rights at 165,538,736. This update is crucial for stakeholders as it reflects the company’s current equity structure, which may influence shareholder value and decision-making.
More about Sartorius Stedim Biotech
Sartorius Stedim Biotech is a company operating in the biotechnology sector, providing products and services primarily focused on the development and manufacture of biopharmaceutical products. The company is known for its innovative solutions that support the biotech industry in areas such as cell culture, fermentation, filtration, purification, and fluid management.
YTD Price Performance: 19.77%
Average Trading Volume: 42,143
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €21.74B
Find detailed analytics on DIM stock on TipRanks’ Stock Analysis page.
